5VM
5AM Venture Management Portfolio holdings
AUM
$260M
This Quarter Return
+8.58%
1 Year Return
+3.76%
3 Year Return
+144.87%
5 Year Return
+32.61%
10 Year Return
–
AUM
$391M
AUM Growth
+$391M
(+5.1%)
Cap. Flow
+$61.9M
Cap. Flow
% of AUM
15.82%
Top 10 Holdings %
Top 10 Hldgs %
80.82%
Holding
26
New
5
Increased
1
Reduced
5
Closed
2
Top Buys
| 1 |
Enliven Therapeutics
ELVN
|
$127M |
| 2 |
FibroGen
FGEN
|
$6.6M |
| 3 |
Viking Therapeutics
VKTX
|
$5.83M |
| 4 |
SPRB
Spruce Biosciences, Inc. Common Stock
SPRB
|
$5.22M |
| 5 |
Mersana Therapeutics
MRSN
|
$4.87M |
Top Sells
| 1 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
$60.7M |
| 2 |
scPharmaceuticals
SCPH
|
$13.9M |
| 3 |
Janux Therapeutics
JANX
|
$5.88M |
| 4 |
IDEAYA Biosciences
IDYA
|
$4.5M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$2.43M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Enliven Therapeutics
ELVN
$1.2B
| $127M | 32.47% | +5,798,475 | New | +$127M |
|
2
Entrada Therapeutics
TRDA
$208M
| $63.9M | 16.35% | 4,408,379 | – | – |
|
3
Vor Biopharma
VOR
$250M
| $34.2M | 8.75% | 6,361,723 | – | – |
|
4
Rallybio
RLYB
$22.4M
| $20.7M | 5.3% | 3,630,724 -100,000 | -3% | -$571K |
|
5
Crinetics Pharmaceuticals
CRNX
$2.92B
| $13.8M | 3.54% | 862,286 | – | – |
|
6
Disc Medicine
IRON
$2.07B
| $12.5M | 3.19% | 588,442 | – | – |
|
|
7
IDEAYA Biosciences
IDYA
$2.15B
| $11.9M | 3.05% | 868,520 -327,778 | -27% | -$4.5M |
|
|
8
scPharmaceuticals
SCPH
$295M
| $10.9M | 2.78% | 1,200,647 -1,534,205 | -56% | -$13.9M |
|
|
9
FibroGen
FGEN
$47.8M
| $10.8M | 2.77% | 579,434 +353,851 | +157% | +$6.6M |
|
10
Avidity Biosciences
RNA
$5.99B
| $10.2M | 2.61% | 665,555 | – | – |
|
11
Arvinas
ARVN
$568M
| $8.74M | 2.24% | 320,000 | – | – |
|
12
Cogent Biosciences
COGT
$1.69B
| $8.53M | 2.18% | 790,440 | – | – |
|
13
AnaptysBio
ANAB
$569M
| $7.78M | 1.99% | 357,733 | – | – |
|
14
Viridian Therapeutics
VRDN
$1.5B
| $7.12M | 1.82% | 280,000 -20,000 | -7% | -$509K |
|
|
ISEE
15
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $6.92M | 1.77% | 284,626 -100,000 | -26% | -$2.43M |
|
|
16
Viking Therapeutics
VKTX
$3.04B
| $5.83M | 1.49% | +350,000 | New | +$5.83M |
|
|
SPRB
17
DELISTED
Spruce Biosciences, Inc. Common Stock
SPRB
| $5.22M | 1.34% | +2,364,000 | New | +$5.22M |
|
|
18
Mersana Therapeutics
MRSN
$36.5M
| $4.87M | 1.25% | +1,185,000 | New | +$4.87M |
|
19
Pharvaris
PHVS
$1.39B
| $4.73M | 1.21% | 587,600 | – | – |
|
20
Q32 Bio
QTTB
$20.9M
| $4.67M | 1.19% | 4,535,919 | – | – |
|
|
PEAR
21
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
| $4.27M | 1.09% | 16,744,113 | – | – |
|
|
IMPL
22
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
| $4.04M | 1.03% | 2,884,791 | – | – |
|
23
Cidara Therapeutics
CDTX
$1.66B
| $1.44M | 0.37% | 1,134,511 | – | – |
|
24
MoonLake Immunotherapeutics
MLTX
$3.54B
| $831K | 0.21% | +38,856 | New | +$831K |
|
|
25
Janux Therapeutics
JANX
$1.37B
| – | – | -446,266 | Closed | -$5.88M |
|